FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4309660584> ?p ?o ?g. }

• W4309660584 endingPage "117955492211371" @default.
• W4309660584 startingPage "117955492211371" @default.
• W4309660584 abstract "A trial with trifluridine/tipiracil (FTD/TPI) versus placebo in patients with heavily pretreated metastatic gastric cancer showed that FTD/TPI is effective with manageable toxicity in these patients. However, real-world data on the effects of FTD/TPI in patients with advanced gastric cancer (AGC) are limited.We retrospectively collected and analyzed the clinicopathological data of patients with AGC who received FTD/TPI monotherapy at our institutions (Kobe City Medical Center General Hospital, Osaka Red Cross Hospital, Himeji Red Cross Hospital, and Kansai Medical University Hospital) between September 2019 and July 2021. Tumor responses were evaluated based on the Response Evaluation Criteria in Solid Tumors, version 1.1. Overall survival (OS) and progression-free survival were estimated using the Kaplan-Meier method.A total of 53 patients were included in the study. The median age was 70 (range, 37-85) years; 39 patients (74%) were men; the numbers of patients with Eastern Cooperative Oncology Group performance status scores of 0, 1, and 2 were 10 (19%), 39 (74%), and 4 (8%), respectively; and 27 patients (51%) had diffuse-type histology. A total of 29 patients (56%) had ascites. Prior nivolumab therapy was administered to 49 patients (92%). The response rate and disease control rate (DCR) were 2% and 35%, respectively. The median progression-free survival was 2.4 months, and OS was 5.8 months. Patients with ascites exhibited significantly shorter OS (8.6 vs 4.7 months, P = .0291) than those without ascites, and DCR (54% vs 18%, P = .0055) was significantly worse in patients with ascites. There was no significant difference in the frequency of adverse events of grade 3 or higher between patients with and without ascites.In a real-world setting, FTD/TPI has similar effectiveness as late-line chemotherapy for patients with AGC, including those who previously had received nivolumab." @default.
• W4309660584 created "2022-11-29" @default.
• W4309660584 creator A5003272799 @default.
• W4309660584 creator A5006249981 @default.
• W4309660584 creator A5018537494 @default.
• W4309660584 creator A5025304476 @default.
• W4309660584 creator A5025823595 @default.
• W4309660584 creator A5031013161 @default.
• W4309660584 creator A5039116635 @default.
• W4309660584 creator A5039675116 @default.
• W4309660584 creator A5045819149 @default.
• W4309660584 creator A5057155489 @default.
• W4309660584 creator A5067776411 @default.
• W4309660584 creator A5068132612 @default.
• W4309660584 creator A5070398281 @default.
• W4309660584 creator A5074800153 @default.
• W4309660584 creator A5075964384 @default.
• W4309660584 creator A5087517300 @default.
• W4309660584 creator A5090972080 @default.
• W4309660584 date "2022-01-01" @default.
• W4309660584 modified "2023-09-26" @default.
• W4309660584 title "Real-World Data of Trifluridine/Tipiracil for Patients With Advanced Gastric Cancer: A Multi-Institutional Retrospective Study" @default.
• W4309660584 cites W1974054076 @default.
• W4309660584 cites W2022324307 @default.
• W4309660584 cites W2085752449 @default.
• W4309660584 cites W2096052239 @default.
• W4309660584 cites W242040007 @default.
• W4309660584 cites W2743577629 @default.
• W4309660584 cites W2754547251 @default.
• W4309660584 cites W2763064222 @default.
• W4309660584 cites W2774682757 @default.
• W4309660584 cites W2889646458 @default.
• W4309660584 cites W2897154408 @default.
• W4309660584 cites W3005381361 @default.
• W4309660584 cites W3043075404 @default.
• W4309660584 cites W3087539333 @default.
• W4309660584 cites W3093660586 @default.
• W4309660584 cites W3125158795 @default.
• W4309660584 cites W3171517418 @default.
• W4309660584 cites W4206384216 @default.
• W4309660584 doi "https://doi.org/10.1177/11795549221137135" @default.
• W4309660584 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36408335" @default.
• W4309660584 hasPublicationYear "2022" @default.
• W4309660584 type Work @default.
• W4309660584 citedByCount "0" @default.
• W4309660584 crossrefType "journal-article" @default.
• W4309660584 hasAuthorship W4309660584A5003272799 @default.
• W4309660584 hasAuthorship W4309660584A5006249981 @default.
• W4309660584 hasAuthorship W4309660584A5018537494 @default.
• W4309660584 hasAuthorship W4309660584A5025304476 @default.
• W4309660584 hasAuthorship W4309660584A5025823595 @default.
• W4309660584 hasAuthorship W4309660584A5031013161 @default.
• W4309660584 hasAuthorship W4309660584A5039116635 @default.
• W4309660584 hasAuthorship W4309660584A5039675116 @default.
• W4309660584 hasAuthorship W4309660584A5045819149 @default.
• W4309660584 hasAuthorship W4309660584A5057155489 @default.
• W4309660584 hasAuthorship W4309660584A5067776411 @default.
• W4309660584 hasAuthorship W4309660584A5068132612 @default.
• W4309660584 hasAuthorship W4309660584A5070398281 @default.
• W4309660584 hasAuthorship W4309660584A5074800153 @default.
• W4309660584 hasAuthorship W4309660584A5075964384 @default.
• W4309660584 hasAuthorship W4309660584A5087517300 @default.
• W4309660584 hasAuthorship W4309660584A5090972080 @default.
• W4309660584 hasBestOaLocation W43096605841 @default.
• W4309660584 hasConcept C121608353 @default.
• W4309660584 hasConcept C126322002 @default.
• W4309660584 hasConcept C141071460 @default.
• W4309660584 hasConcept C167135981 @default.
• W4309660584 hasConcept C195910791 @default.
• W4309660584 hasConcept C2776694085 @default.
• W4309660584 hasConcept C2778822529 @default.
• W4309660584 hasConcept C2779984678 @default.
• W4309660584 hasConcept C2780496750 @default.
• W4309660584 hasConcept C2780739268 @default.
• W4309660584 hasConcept C71924100 @default.
• W4309660584 hasConcept C90924648 @default.
• W4309660584 hasConceptScore W4309660584C121608353 @default.
• W4309660584 hasConceptScore W4309660584C126322002 @default.
• W4309660584 hasConceptScore W4309660584C141071460 @default.
• W4309660584 hasConceptScore W4309660584C167135981 @default.
• W4309660584 hasConceptScore W4309660584C195910791 @default.
• W4309660584 hasConceptScore W4309660584C2776694085 @default.
• W4309660584 hasConceptScore W4309660584C2778822529 @default.
• W4309660584 hasConceptScore W4309660584C2779984678 @default.
• W4309660584 hasConceptScore W4309660584C2780496750 @default.
• W4309660584 hasConceptScore W4309660584C2780739268 @default.
• W4309660584 hasConceptScore W4309660584C71924100 @default.
• W4309660584 hasConceptScore W4309660584C90924648 @default.
• W4309660584 hasLocation W43096605841 @default.
• W4309660584 hasLocation W43096605842 @default.
• W4309660584 hasLocation W43096605843 @default.
• W4309660584 hasOpenAccess W4309660584 @default.
• W4309660584 hasPrimaryLocation W43096605841 @default.
• W4309660584 hasRelatedWork W1586374228 @default.
• W4309660584 hasRelatedWork W2003938723 @default.
• W4309660584 hasRelatedWork W2047967234 @default.
• W4309660584 hasRelatedWork W2088161755 @default.
• W4309660584 hasRelatedWork W2118496982 @default.

• next